标题
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-06-28
DOI
10.1038/s41571-018-0055-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IDH1/2Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
- (2018) Remco J. Molenaar et al. CLINICAL CANCER RESEARCH
- Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells
- (2018) Juan I. Garaycoechea et al. NATURE
- Succinate dehydrogenase (SDH)-deficient neoplasia
- (2017) Anthony J Gill HISTOPATHOLOGY
- The genetic landscape of endometrial clear cell carcinomas
- (2017) Deborah F DeLair et al. JOURNAL OF PATHOLOGY
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers
- (2017) Amy Dréan et al. MOLECULAR CANCER THERAPEUTICS
- Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
- (2017) Prasenjit Dey et al. NATURE
- Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
- (2017) Di Zhao et al. NATURE
- ARID1A-mutated ovarian cancers depend on HDAC6 activity
- (2017) Benjamin G. Bitler et al. NATURE CELL BIOLOGY
- Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells
- (2017) Robin M Meyers et al. NATURE GENETICS
- Marked for death: targeting epigenetic changes in cancer
- (2017) Sophia Xiao Pfister et al. NATURE REVIEWS DRUG DISCOVERY
- Emerging and evolving concepts in gene essentiality
- (2017) Giulia Rancati et al. NATURE REVIEWS GENETICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
- (2017) Thomas Januario et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
- (2017) Abhishek A. Chakraborty et al. Science Translational Medicine
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
- (2017) Georg Karpel-Massler et al. Nature Communications
- Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer
- (2017) Hui Liu et al. Cancer Discovery
- Synthetic Lethal Vulnerabilities in KRAS -Mutant Cancers
- (2017) Andrew J. Aguirre et al. Cold Spring Harbor Perspectives in Medicine
- A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events
- (2017) Colm J. Ryan et al. Cell Systems
- Targeting MYC in cancer therapy: RNA processing offers new opportunities
- (2016) Cheryl M. Koh et al. BIOESSAYS
- Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens
- (2016) Atray Dixit et al. CELL
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Comprehensive mutation profiling of mucinous gastric carcinoma
- (2016) Hirofumi Rokutan et al. JOURNAL OF PATHOLOGY
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
- (2016) Jonathan A Ledermann et al. LANCET ONCOLOGY
- Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
- (2016) Rowan E. Miller et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
- (2016) Roman Camarda et al. NATURE MEDICINE
- PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression
- (2016) Dai Horiuchi et al. NATURE MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma
- (2016) J M Thompson et al. ONCOGENE
- Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
- (2016) Konstantinos J. Mavrakis et al. SCIENCE
- MTAPdeletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
- (2016) Gregory V. Kryukov et al. SCIENCE
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
- (2016) James Campbell et al. Cell Reports
- MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
- (2016) Katya Marjon et al. Cell Reports
- Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage
- (2016) Cosetta Bertoli et al. Cell Reports
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
- (2015) Felix Dietlein et al. CELL
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
- (2015) Marwan Kwok et al. LANCET
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
- (2015) Pedro A. Mateos-Gomez et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis
- (2015) Simone Cardaci et al. NATURE CELL BIOLOGY
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
- (2015) Kimberly H Kim et al. NATURE MEDICINE
- Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
- (2015) Benjamin G Bitler et al. NATURE MEDICINE
- Targeting Notch, Hedgehog and Wnt pathways in cancer stem cells: clinical update
- (2015) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
- (2015) Evrim Gurpinar et al. TRENDS IN CELL BIOLOGY
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
- (2015) J. Shen et al. Cancer Discovery
- Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics
- (2015) C. Kadoch et al. Science Advances
- Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition
- (2015) Eleftherios P. Samartzis et al. Oncotarget
- ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
- (2014) K. N. Mohni et al. CANCER RESEARCH
- BRG1/SMARCA4 Inactivation Promotes Non-Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization
- (2014) T. Orvis et al. CANCER RESEARCH
- Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response
- (2014) E. Grabocka et al. CLINICAL CANCER RESEARCH
- Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
- (2014) B. G. Wilson et al. MOLECULAR AND CELLULAR BIOLOGY
- ARID1B is a specific vulnerability in ARID1A-mutant cancers
- (2014) Katherine C Helming et al. NATURE MEDICINE
- Targeting RNA polymerase I to treat MYC-driven cancer
- (2014) G Poortinga et al. ONCOGENE
- Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
- (2014) G. R. Hoffman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
- (2013) K. Cramer-Morales et al. BLOOD
- A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
- (2013) T. Oike et al. CANCER RESEARCH
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- Survival of the Replication Checkpoint Deficient Cells Requires MUS81-RAD52 Function
- (2013) Ivana Murfuni et al. PLoS Genetics
- The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
- (2012) Madhu S. Kumar et al. CELL
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
- (2012) Michael Steckel et al. CELL RESEARCH
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Passenger deletions generate therapeutic vulnerabilities in cancer
- (2012) Florian L. Muller et al. NATURE
- Synthetic lethality between Rb, p53 and Dicer or miR-17–92 in retinal progenitors suppresses retinoblastoma formation
- (2012) David Nittner et al. NATURE CELL BIOLOGY
- Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators
- (2012) Akihiro Fujimoto et al. NATURE GENETICS
- Functional genomics identifies therapeutic targets for MYC-driven cancer
- (2012) M. Toyoshima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The p53 network: cellular and systemic DNA damage responses in aging and cancer
- (2012) H. Christian Reinhardt et al. TRENDS IN GENETICS
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
- (2011) Thomas De Raedt et al. CANCER CELL
- STK33 Kinase Is Not Essential in KRAS-Dependent Cells-Letter
- (2011) S. Frohling et al. CANCER RESEARCH
- Genetic Interactions in Cancer Progression and Treatment
- (2011) Alan Ashworth et al. CELL
- Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin
- (2011) S. Chantalat et al. GENOME RESEARCH
- Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
- (2011) Christian Frezza et al. NATURE
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
- (2011) J. D. Kessler et al. SCIENCE
- Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
- (2011) Richard Marcotte et al. Cancer Discovery
- Specific Killing of Rb Mutant Cancer Cells by Inactivating TSC2
- (2010) Binghui Li et al. CANCER CELL
- Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
- (2010) O. Gilad et al. CANCER RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rad52 inactivation is synthetically lethal with BRCA2 deficiency
- (2010) Z. Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling Complex
- (2009) X. Wang et al. CANCER RESEARCH
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Cdk2 suppresses cellular senescence induced by the c-myc oncogene
- (2009) Stefano Campaner et al. NATURE CELL BIOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing
- (2009) K. J. McManus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy
- (2008) Sandra Turcotte et al. CANCER CELL
- Evolutionary plasticity of genetic interaction networks
- (2008) Julia Tischler et al. NATURE GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started